Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Entelon150® (Vitis vinifera Seed Extract) Attenuates Degenerative Changes in Intravascular Valve Prostheses in Rabbits

  • Jue Seong Lee (Department of Pediatrics, Korea University Anam Hospital, Korea University College of Medicine) ;
  • JungHyeok Seo (Department of Surgery, College of Veterinary Medicine, Jeonbuk National University) ;
  • Sokho Kim (Department of Laboratory Animal Medicine, College of Veterinary Medicine, Jeonbuk National University) ;
  • Md. Mahbubur Rahman (Department of Physiology, Gachon University College of Medicine) ;
  • Hong Ju Shin (Department of Thoracic and Cardiovascular Surgery, Myoungju Hospital)
  • Received : 2023.05.06
  • Accepted : 2023.08.16
  • Published : 2024.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background and Objectives: The therapeutic strategy for inflammation and degenerative calcification is of utmost importance for bioprosthetic heart valve (BHV) implanted patients. The purpose of this study was to compare the anti-inflammatory and anti-calcification effects of Entelon150® (grape seed extract), losartan, and rosuvastatin, in a rabbit model of intravascular BHV leaflet implantation in bovine pericardium. Methods: A total of 28 rabbits were implanted with BHV leaflet in the external jugular veins. The Entelon150® group was administered 7.7 mg/kg Entelon150® twice daily for 6 weeks after surgery. The losartan and rosuvastatin groups received 5.14 mg/kg and 1 mg/kg, respectively, once per day. The control group received 1 ml of saline once daily. And then, calcium concentration was measured in the implanted BHV, and histological and molecular analyses were performed on the surrounding tissues. Results: The calcium content of the implanted tissue in the Entelon150® group (0.013±0.004 mg/g) was lower than that in the control group (0.066±0.039 mg/g) (p=0.008). The losartan (0.024±0.016 mg/g, p=0.032) and rosuvastatin (0.022±0.011 mg/g, p=0.032) groups had lower calcium content than the control group, and higher tendency than the Entelon150® group. Immunohistochemistry revealed that the expressions of bone morphogenic protein 2 (BMP2), S-100, and angiotensin II type 1 receptor in the Entelon150® group showed lower tendency than those in the control group. The protein expression levels of BMP2 were reduced in the Entelon150® group compared with those in the control group. Conclusions: Entelon150® exhibited a significant effect, similar to other drugs, in reducing calcification and inflammation in the intravascular bovine pericardium.

Keywords

Acknowledgement

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2021R1G1A101339812).

References

  1. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg 2005;79:1072-80.
  2. Lee S, Levy RJ, Christian AJ, et al. Calcification and oxidative modifications are associated with progressive bioprosthetic heart valve dysfunction. J Am Heart Assoc 2017;6:e005648.
  3. Kim DH, Park HK, Park YH, et al. Degenerative calcification of pericardial bioprostheses: comparison of five implantation methods in a rabbit model. J Heart Valve Dis 2015;24:621-8.
  4. Colli A, Gherli T, Mestres CA, Pomar JL. Degeneration of native and tissue prosthetic valve in aortic position: do statins play an effective role in prevention? Int J Cardiol 2007;116:144-52.
  5. Cote N, Couture C, Pibarot P, Despres JP, Mathieu P. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. Eur J Clin Invest 2011;41:1172-9.
  6. Aggarwal RK, Showkathali R. Rosuvastatin calcium in acute coronary syndromes. Expert Opin Pharmacother 2013;14:1215-27.
  7. Lee S, Kim DH, Youn YN, Joo HC, Yoo KJ, Lee SH. Rosuvastatin attenuates bioprosthetic heart valve calcification. J Thorac Cardiovasc Surg 2019;158:731-741.e1.
  8. Choi GC, Kim S, Rahman MM, Oh JH, Cho YS, Shin HJ. Entelon (vitis vinifera seed extract) reduces degenerative changes in bovine pericardium valve leaflet in a dog intravascular implant model. PLoS One 2021;16:e0235454.
  9. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 2016;7:27-31.
  10. Nandakumar V, Singh T, Katiyar SK. Multi-targeted prevention and therapy of cancer by proanthocyanidins. Cancer Lett 2008;269:378-87.
  11. Kaur M, Agarwal C, Agarwal R. Anticancer and cancer chemopreventive potential of grape seed extract and other grape-based products. J Nutr 2009;139:1806S-1812S.
  12. Wang H, Xue Y, Zhang H, et al. Dietary grape seed extract ameliorates symptoms of inflammatory bowel disease in IL10-deficient mice. Mol Nutr Food Res 2013;57:2253-7.
  13. Zhang Y, Shi H, Wang W, et al. Antithrombotic effect of grape seed proanthocyanidins extract in a rat model of deep vein thrombosis. J Vasc Surg 2011;53:743-53.
  14. Singh RP, Tyagi AK, Dhanalakshmi S, Agarwal R, Agarwal C. Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3. Int J Cancer 2004;108:733-40.
  15. Dvir D, Bourguignon T, Otto CM, et al. Standardized definition of structural valve degeneration for surgical and transcatheter bioprosthetic aortic valves. Circulation 2018;137:388-99.
  16. Wen S, Zhou Y, Yim WY, et al. Mechanisms and drug therapies of bioprosthetic heart valve calcification. Front Pharmacol 2022;13:909801.
  17. Lorusso R, Corradi D, Maestri R, et al. Atorvastatin attenuates post-implant tissue degeneration of cardiac prosthetic valve bovine pericardial tissue in a subcutaneous animal model. Int J Cardiol 2010;141:68-74.
  18. Eishi K, Ishibashi-Ueda H, Nakano K, et al. Calcific degeneration of bioprosthetic aortic valves in patients receiving steroid therapy. J Heart Valve Dis 1996;5:668-72.
  19. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007;21:1387-94.
  20. Shin HJ, Kim DH, Park HK, Park YH. The angiotensin II type 1 receptor blocker losartan attenuates bioprosthetic valve leaflet calcification in a rabbit intravascular implant model. Eur J Cardiothorac Surg 2016;50:1045-52.
  21. Zhang M, Sara JD, Wang FL, et al. Increased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patients. Cardiovasc Diabetol 2015;14:64.
  22. Xia C, Braunstein Z, Toomey AC, Zhong J, Rao X. S100 proteins as an important regulator of macrophage inflammation. Front Immunol 2018;8:1908.
  23. O'Brien KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006;26:1721-8.
  24. Latif N, Sarathchandra P, Chester AH, Yacoub MH. Expression of smooth muscle cell markers and coactivators in calcified aortic valves. Eur Heart J 2015;36:1335-45.
  25. Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005;44:797-814.
  26. Toth PP, Dayspring TD. Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf 2011;10:969-86.
  27. Meuris B, Ozaki S, Herijgers P, Verbeken E, Flameng W. Bioprosthetic tissue calcification: influence of blood contact and arterial pressure. an experimental study in rats and sheep. J Heart Valve Dis 2003;12:392-9.